For early prediction of cardiotoxicity in cancer patients, blood levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and myeloperoxidase (MPO) can be measured (Ky et al. 2014; Lu et al. 2019). Here, MPO is linked to cancer.